UPDATE: Morgan Stanley Reiterates On Albany Molecular Research Ahead Of Conference Call

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Albany Molecular Research AMRI, but removed the $21.00 price target. In the report, Morgan Stanley noted, “We are hosting AMRI's CEO Bill Marth and CFO Mike Nolan today, June 16th at 2pm ET as part of our CEO/CFO conference call series. On the call we will discuss key investor questions, highlighted below.” Albany Molecular Research closed on Friday at $18.58.